AbbVie completes acquisition of Celsius Therapeutics, Inc. to advance therapies for inflammatory disease
AbbVie completes acquisition of Celsius Therapeutics, Inc. to advance therapies for inflammatory disease
06/27/24, 1:29 PM
Location
north chicagocambridgeIndustry
healthcare
AbbVie, a pharmaceutical company focused on discovering innovative medicines, has successfully completed the acquisition of Celsius Therapeutics, Inc. This acquisition aligns with AbbVie's commitment to developing novel therapies for inflammatory disease and advancing the potential of CEL383, an anti-TREM1 antibody for the treatment of IBD.
Company Info
Location
North Chicago, Illinois, United States
Company info
Cerevel Therapeutics is a biopharmaceutical company dedicated to developing therapies for neuroscience. It focuses on curing diseases associated with the central nervous system, specializing in treating disorders such as schizophrenia and epilepsy. Cerevel is known for its innovative approaches to complex neurological conditions. The company went public and was listed on NASDAQ under the ticker symbol CERE.